ArticleInternal medicine (Tokyo, Japan)2018

The Efficacy of Reduced-dose Dasatinib as a Subsequent Therapy in Patients with Chronic Myeloid Leukemia in the Chronic Phase: The LD-CML Study of the Kanto CML Study Group.

Noriyoshi Iriyama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.